Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Identification and Characterization of Mutations in Ubiquitin Required for Non-covalent Dimer Formation.

Gabrielsen M, Buetow L, Kowalczyk D, Zhang W, Sidhu SS, Huang DT.

Structure. 2019 Sep 3;27(9):1452-1459.e4. doi: 10.1016/j.str.2019.06.008. Epub 2019 Jul 11.

2.

Single-Turnover RING/U-Box E3-Mediated Lysine Discharge Assays.

Buetow L, Gabrielsen M, Huang DT.

Methods Mol Biol. 2018;1844:19-31. doi: 10.1007/978-1-4939-8706-1_2.

PMID:
30242700
3.

A General Strategy for Discovery of Inhibitors and Activators of RING and U-box E3 Ligases with Ubiquitin Variants.

Gabrielsen M, Buetow L, Nakasone MA, Ahmed SF, Sibbet GJ, Smith BO, Zhang W, Sidhu SS, Huang DT.

Mol Cell. 2017 Oct 19;68(2):456-470.e10. doi: 10.1016/j.molcel.2017.09.027.

4.

Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation.

Buetow L, Tria G, Ahmed SF, Hock A, Dou H, Sibbet GJ, Svergun DI, Huang DT.

BMC Biol. 2016 Sep 8;14:76. doi: 10.1186/s12915-016-0298-6.

5.

Structural insights into the catalysis and regulation of E3 ubiquitin ligases.

Buetow L, Huang DT.

Nat Rev Mol Cell Biol. 2016 Oct;17(10):626-42. doi: 10.1038/nrm.2016.91. Epub 2016 Aug 3. Review.

6.

Activation of a primed RING E3-E2-ubiquitin complex by non-covalent ubiquitin.

Buetow L, Gabrielsen M, Anthony NG, Dou H, Patel A, Aitkenhead H, Sibbet GJ, Smith BO, Huang DT.

Mol Cell. 2015 Apr 16;58(2):297-310. doi: 10.1016/j.molcel.2015.02.017. Epub 2015 Mar 19.

7.

Essentiality of a non-RING element in priming donor ubiquitin for catalysis by a monomeric E3.

Dou H, Buetow L, Sibbet GJ, Cameron K, Huang DT.

Nat Struct Mol Biol. 2013 Aug;20(8):982-986. doi: 10.1038/nsmb.2621. Epub 2013 Jul 14.

8.

BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer.

Dou H, Buetow L, Sibbet GJ, Cameron K, Huang DT.

Nat Struct Mol Biol. 2012 Sep;19(9):876-83. doi: 10.1038/nsmb.2379. Epub 2012 Aug 14.

9.

Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl.

Dou H, Buetow L, Hock A, Sibbet GJ, Vousden KH, Huang DT.

Nat Struct Mol Biol. 2012 Jan 22;19(2):184-92. doi: 10.1038/nsmb.2231.

10.

Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Reply to Schatz H [letter].

Vella S, Buetow L, Royle P, Livingstone S, Petrie JR.

Diabetologia. 2011 Jan;54(1):203-4. doi: 10.1007/s00125-010-1953-z. Epub 2010 Oct 29. No abstract available.

PMID:
21046359
11.

The use of metformin in type 1 diabetes: a systematic review of efficacy.

Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR.

Diabetologia. 2010 May;53(5):809-20. doi: 10.1007/s00125-009-1636-9. Epub 2010 Jan 8. Review.

PMID:
20057994
12.

A structure-based approach to ligand discovery for 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase: a target for antimicrobial therapy.

Ramsden NL, Buetow L, Dawson A, Kemp LA, Ulaganathan V, Brenk R, Klebe G, Hunter WN.

J Med Chem. 2009 Apr 23;52(8):2531-42. doi: 10.1021/jm801475n.

13.

Structure of Staphylococcus aureus1,4-dihydroxy-2-naphthoyl-CoA synthase (MenB) in complex with acetoacetyl-CoA.

Ulaganathan V, Agacan MF, Buetow L, Tulloch LB, Hunter WN.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Nov 1;63(Pt 11):908-13. Epub 2007 Oct 20.

15.

Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: potential for drug development.

Eoh H, Brown AC, Buetow L, Hunter WN, Parish T, Kaur D, Brennan PJ, Crick DC.

J Bacteriol. 2007 Dec;189(24):8922-7. Epub 2007 Oct 5.

16.

Nucleotide substrate recognition by UDP-N-acetylglucosamine acyltransferase (LpxA) in the first step of lipid A biosynthesis.

Ulaganathan V, Buetow L, Hunter WN.

J Mol Biol. 2007 Jun 1;369(2):305-12. Epub 2007 Mar 21.

PMID:
17434525
17.

Structure and reactivity of LpxD, the N-acyltransferase of lipid A biosynthesis.

Buetow L, Smith TK, Dawson A, Fyffe S, Hunter WN.

Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4321-6. Epub 2007 Mar 5.

18.

The nucleotide-binding site of Aquifex aeolicus LpxC.

Buetow L, Dawson A, Hunter WN.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Nov 1;62(Pt 11):1082-6. Epub 2006 Oct 25.

19.

Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids.

Fyffe SA, Alphey MS, Buetow L, Smith TK, Ferguson MA, Sørensen MD, Björkling F, Hunter WN.

J Mol Biol. 2006 Mar 3;356(4):1005-13. Epub 2006 Jan 4.

PMID:
16405912
20.

Reevaluation of the PPAR-beta/delta ligand binding domain model reveals why it exhibits the activated form.

Fyffe SA, Alphey MS, Buetow L, Smith TK, Ferguson MA, Sørensen MD, Björkling F, Hunter WN.

Mol Cell. 2006 Jan 6;21(1):1-2. No abstract available.

21.

Structural elements required for deamidation of RhoA by cytotoxic necrotizing factor 1.

Buetow L, Ghosh P.

Biochemistry. 2003 Nov 11;42(44):12784-91.

PMID:
14596592
22.

Strategies for the structural determination of the catalytic domain of Escherichia coli cytotoxic necrotizing factor 1.

Buetow L, Flatau G, Chiu K, Boquet P, Ghosh P.

Acta Crystallogr D Biol Crystallogr. 2002 Feb;58(Pt 2):366-9. Epub 2002 Jan 24.

PMID:
11807279
23.

Structure of the Rho-activating domain of Escherichia coli cytotoxic necrotizing factor 1.

Buetow L, Flatau G, Chiu K, Boquet P, Ghosh P.

Nat Struct Biol. 2001 Jul;8(7):584-8.

PMID:
11427886

Supplemental Content

Loading ...
Support Center